| Bioactivity | Rovelizumab is a humanized monoclonal leukointegrin antibody. Rovelizumab is a monoclonal antibody directed against the CD11/CD18 cell adhesion proteins. Rovelizumab can be used for research of multiple sclerosis (MS), hemorrhagic shock, myocardial infarction (MI) and stroke[1]. |
| Invitro | Rovelizumab 结合 CD18 并对 CD18 整合素复合物具有活性，包括 CD11b-CD18 异源二聚体[2]。 |
| Name | Rovelizumab |
| CAS | 339086-79-2 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Jones R. Rovelizumab (ICOS Corp). IDrugs. 2000 Apr;3(4):442-6. [2]. Qualls JE, et al. A double agent in cancer: stopping macrophages wounds tumors. Nat Med. 2010 Aug;16(8):863-4. |